<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Head Neck Pathol</journal-id><journal-id journal-id-type="iso-abbrev">Head Neck Pathol</journal-id><journal-title-group><journal-title>Head and Neck Pathology</journal-title></journal-title-group><issn pub-type="ppub">1936-055X</issn><issn pub-type="epub">1936-0568</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40392349</article-id><article-id pub-id-type="pmc">PMC12092928</article-id>
<article-id pub-id-type="publisher-id">1798</article-id><article-id pub-id-type="doi">10.1007/s12105-025-01798-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>High-Sensitivity PD-L1 Staining Using Clone 73&#x02212;10 Antibody and Spatial Transcriptomics for Precise Expression Analysis in Non-Tumorous, Intraepithelial Neoplasia, and Squamous Cell Carcinoma of Head and Neck</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8041-0074</contrib-id><name><surname>Noda</surname><given-names>Yuri</given-names></name><address><email>nodayuridesu@yahoo.co.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Atsumi</surname><given-names>Naho</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Nakaya</surname><given-names>Takeo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Iwai</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tsuta</surname><given-names>Koji</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001xjdh50</institution-id><institution-id institution-id-type="GRID">grid.410783.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2172 5041</institution-id><institution>Department of Pathology and Laboratory Medicine, </institution><institution>Kansai Medical University Hospital, </institution></institution-wrap>2-3-1 Shin-machi, Hirakata, Osaka, 573-1191 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001xjdh50</institution-id><institution-id institution-id-type="GRID">grid.410783.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2172 5041</institution-id><institution>Department of Pathology, </institution><institution>Kansai Medical University, </institution></institution-wrap>2-5-1 Shin-machi, Hirakata, Osaka, 573-1010 Japan </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001xjdh50</institution-id><institution-id institution-id-type="GRID">grid.410783.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 2172 5041</institution-id><institution>Department of Otolaryngology, Head and Neck Surgery, </institution><institution>Kansai Medical University Hospital, </institution></institution-wrap>2-3-1 Shinmachi, Hirakata, Osaka, 5731191 Japan </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>19</volume><issue>1</issue><elocation-id>65</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p id="Par1">While immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have improved outcomes in head and neck squamous cell carcinoma (HNSCC), eligibility criteria based on immunohistochemistry (IHC) target PD-1 solely. We aimed to evaluate the PD-L1 (<italic>CD274</italic>) expression using highly sensitive clone 73&#x02009;&#x02212;&#x02009;10 and spatial transcriptomics (ST) analysis to elucidate the role of PD-L1 in HNSCC and thus potentially expand the pool of eligible patients.</p></sec><sec><title>Methods</title><p id="Par2">Immunohistochemical staining of 73&#x02009;&#x02212;&#x02009;10, CD3, CD4, and CD8 were performed in 94 HNSCC clinical samples along with paired adjacent squamous intraepithelial neoplasm (SIN) and normal oral mucosa (NOM) samples. The 73&#x02009;&#x02212;&#x02009;10 positivity was evaluated using a tumor cell score&#x02009;&#x02265;&#x02009;1%, and the results were analyzed against clinicopathological features including CD4<sup>+</sup> and CD8<sup>+</sup> tumor-infiltrating lymphocytes (TILs), and clinical outcomes. Furthermore, ST and PD-L1 related pathway analysis was performed in 6 paired HNSCC, SIN and NOM samples.</p></sec><sec><title>Results</title><p id="Par3">The 73&#x02009;&#x02212;&#x02009;10 detected-PD-L1 positivity was high in HNSCC (79%) compared to SIN (10%) and NOM (3%). 73&#x02009;&#x02212;&#x02009;10<sup>+</sup> correlated with high CD4<sup>+</sup> TILs, as well as the independent prognostic factor of OS, DSS, and PFS of HNSCC (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). ST analysis revealed that the upregulated distribution of <italic>CD274</italic> correlated with 73&#x02009;&#x02212;&#x02009;10 positivity. Pathway analysis revealed a significant upregulation of <italic>CD274</italic> and C<italic>D4</italic> in HNSCC compared to SIN and NOM, and HIF-1&#x003b1; and IFN-&#x003b3; as key regulators of PD-L1 expression in HNSCC.</p></sec><sec><title>Conclusion</title><p id="Par4">Clone 73&#x02009;&#x02212;&#x02009;10 is a relatively suitable candidate for identifying patients with PD-L1 expression eligible for ICI therapy. It demonstrates high sensitivity in detecting PD-L1 (<italic>CD274</italic>) in HNSCC, offering immunological and prognostic insights.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12105-025-01798-8.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Oral</kwd><kwd>Head and Neck squamous cell carcinoma</kwd><kwd>PD-L1</kwd><kwd>73&#x02009;&#x02212;&#x02009;10</kwd><kwd>Immune checkpoint inhibitor</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. Its 5-year survival rate is 60%; however, late-stage cases do tend to have a worse prognosis [<xref ref-type="bibr" rid="CR1">1</xref>]. Currently, immune checkpoint inhibitors (ICIs), such as pembrolizumab and nivolumab, blocking the PD-1/PD-L1 axis, have been approved for the treatment of patients with HNSCC who have disease progression or failed platinum-based chemotherapy [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. Although ICIs have improved outcomes in some patients, approximately 60% remain ineligible for treatment [<xref ref-type="bibr" rid="CR5">5</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], and only 15% of those who respond to ICI treatment experience further potential for improvement in patients pre-selected based on PD-L1 expression [<xref ref-type="bibr" rid="CR9">9</xref>]. To address these challenges and broaden the pool of eligible patients, innovative evaluation methods using relatively sensitive antibody clones closely aligned with the mRNA expression profiles of ICI target antigens are urgently needed [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p id="Par6">Immunohistochemistry (IHC) is a commonly employed companion diagnostic tool for assessing patient eligibility for ICI therapies. Recent studies have demonstrated that the 73&#x02009;&#x02212;&#x02009;10 clone exhibits superior sensitivity in detecting PD-L1 expression than the five FDA-approved IHC clones [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. ICIs, such as avelumab, when used to select patients based on 73&#x02009;&#x02212;&#x02009;10 IHC, have shown promise in prolonging survival in patients with non-small cell lung carcinoma [<xref ref-type="bibr" rid="CR12">12</xref>], urothelial carcinoma [<xref ref-type="bibr" rid="CR13">13</xref>], and metastatic breast cancer [<xref ref-type="bibr" rid="CR14">14</xref>]. In HNSCC, a phase I trial (NCT02517398) of bintrafusp alfa, a bifunctional fusion protein targeting TGF-&#x003b2; and PD-L1, revealed outcomes equivalent to those of pembrolizumab and nivolumab treatments. In this study, patients were categorized based on 73&#x02009;&#x02212;&#x02009;10 IHC, using a tumor cell (TC) score threshold of 1% (TC-positive&#x02009;&#x02265;&#x02009;1%, TC-negative&#x02009;&#x0003c;&#x02009;1%) [<xref ref-type="bibr" rid="CR15">15</xref>]. However, no clinicopathological studies have yet examined in detail the role of PD-L1 (<italic>CD274</italic>) and 73&#x02009;&#x02212;&#x02009;10 IHC expression in patients with HNSCC.</p><p id="Par7">Furthermore, the current companion diagnostics of HNSCC target the PD-1 antigen only (clones 22&#x000a0;C-3 and 28&#x02009;&#x02212;&#x02009;8) [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. Therefore, evaluating the PD-1/PD-L1 axis from a novel perspective&#x02014;specifically by assessing PD-L1 expression&#x02014;may expand the pool of potentially eligible patients. Furthermore, to explore the clinical applicability of this approach, IHC-detected PD-L1 protein expression must be validated by correlating it with corresponding mRNA expression (<italic>CD274</italic>) and assessing relevant signaling pathway activity.</p><p id="Par8">In this study, we aimed to evaluate PD-L1 and its mRNA (<italic>CD274</italic>) expression using 73&#x02009;&#x02212;&#x02009;10 IHC and Visium Spatial Transcriptomics (ST) assay&#x02014;a technique that preserves tissue architecture and links mRNA expression to its original location [<xref ref-type="bibr" rid="CR20">20</xref>]&#x02014;to investigate its potential to expand the pool of eligible patients for ICI treatment. In total, 100 patients with progressive HNSCC were included, and the correlation between 73&#x02009;&#x02212;&#x02009;10 expression, mRNA (<italic>CD274</italic>) expression, and their distribution was analyzed. Furthermore, we assessed the clinicopathological features and outcomes of these patients; in addition, we performed pathway analysis to further elucidate the prognostic value of 73&#x02009;&#x02212;&#x02009;10 expression in HNSCC. This study offers a more accurate and reliable method for selecting patients with HNSCC for ICI treatment.</p></sec><sec id="Sec2"><title>Materials and Methods</title><sec id="Sec3"><title>Patients for Clinicopathological Analysis</title><p id="Par9">This retrospective study included 94 patients with progressive HNSCC for clinicopathological IHC analysis who underwent surgical resection at the Department of Otorhinolaryngology, Head and Neck Surgery, Kansai Medical University Hospital, between January 2009 and December 2024. Patients diagnosed with progressive HNSCC at pathological stages pT3 or pT4 and those with non-decalcified formalin-fixed paraffin-embedded (FFPE) blocks were included in this study. This study was approved by the Institutional Review Board (approval number: 2023024). The detailed demographic and clinicopathological characteristics of the patients are provided in Online Resources <xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM2" ref-type="media">2</xref>.</p></sec><sec id="Sec4"><title>Construction of Tissue Microarrays</title><p id="Par10">For clinicopathological analysis, Tissue Microarrays (TMAs) were constructed from 1040 cores, with four cores each from 62 normal oral mucosa (NOM) samples, 94 squamous intraepithelial neoplasm (SIN) samples including mild to severe dysplasia, and 94 HNSCC samples obtained from surgically resected FFPE tissue samples of 94 patients with HNSCC (tissue specimens for TMA cores of HNSCC and SIN were obtained from 94 patients with HNSCC; however, NOM specimens were obtained from 62 of these 94 HNSCC patients). In the present study, we excluded the carcinoma in situ (CIS) from analysis to avoid confusion between CIS and SCC, and considered the genetic differences between dysplasia and CIS. Four HNSCC cores were collected from different invasive areas: two from superficial invasive areas (depth of invasion&#x02009;&#x02264;&#x02009;5&#x000a0;mm) and two from deeper invasive fronts (depth of invasion&#x02009;&#x0003e;&#x02009;6&#x000a0;mm). Each FFPE tissue block was sampled with 2.0-mm cores using a tissue-arraying instrument (Azumaya Corporation, Tokyo, Japan). All selected cores contained at least 100 epithelial cells.</p></sec><sec id="Sec5"><title>Histopathological and Clinicopathological IHC Analyses Using Tissue Microarray</title><p id="Par11">Histopathological analysis was performed on all tissue cores using hematoxylin-eosin (HE)-stained slides made from TMA to evaluate pathological factors within the tumor microenvironment, including desmoplastic reaction (DR), tumor budding (BUD), and tumor-infiltrating lymphocytes (TILs), as described previously [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. For each case, the highest values for each parameter were recorded from each group including NOM, SIN and HNSCC, as they were the most representative of the immune components when present. Additional clinicopathological data were collected from the hospital medical records.</p><p id="Par12">For IHC analysis, tissue sections were incubated with antibodies against 73&#x02009;&#x02212;&#x02009;10 (pre-diluted; Leica Biosystems, Newcastle Upon Tyne, UK), CD3 (PS1, pre-diluted; Nichirei Bioscience, Inc., Tokyo, Japan), CD4 (1F6, pre-diluted; Nichirei Bioscience, Inc.), and CD8 (G2B10, 1:20000; Proteintech Group, Inc. IL, USA). The 73&#x02009;&#x02212;&#x02009;10 antibody was visualized using Leica Bond-III (Leica Biosystems, Melbourne, Australia) and Bond Polymer Refine Detection systems (Leica Biosystems) according to the manufacturer&#x02019;s instructions. For CD3, CD4, and CD8, antigen retrieval was performed using ethylenediaminetetraacetic acid or citrate buffer at 95&#x000a0;&#x000b0;C for 1&#x000a0;h, followed by detection using a Histofine Simple Stain MAX-PO<sup>&#x000ae;</sup> polymer detection system (#NIC-414131&#x000a0;F; Nichirei Bioscience Inc.), and visualization using diaminobenzidine.</p><p id="Par13">The expression of 73&#x02009;&#x02212;&#x02009;10 was evaluated based on the TC score, traditionally defined using the invasive carcinoma components for both the numerator and denominator. However, in the present study, the non-neoplastic epithelium for NOM and the dysplastic components for SIN were used while maintaining the original method for invasive carcinoma components in HNSCC. The TC score was calculated as the percentage of viable epithelial cells exhibiting membrane staining, with TC&#x02009;&#x02265;&#x02009;1% considered positive and TC&#x02009;=&#x02009;0 considered negative [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. The percentage of CD4<sup>+</sup> and CD8<sup>+</sup> TILs was measured and classified as low (&#x0003c;&#x02009;20%) or high (&#x02265;&#x02009;20%) based on CD3<sup>+</sup> areas. Core with low CD4 and CD8 expression were classified as low immune-active, whereas all others were classified as highly immune-active. TC and TILs were assessed in all cores, with the highest values among the four cores each NOM, SIN, and HNSCC were recorded. For assessing the utility of TC in biopsies, the TC of HNSCC was recorded from both the superficial core and the invasive front core.</p></sec><sec id="Sec6"><title>Visium Spatial Transcriptomic Analysis</title><p id="Par14">Visium ST analysis (103 Genomics, Pleasanton, CA, USA) was performed on 18 TMA cores from an additional six patients with progressive HNSCC [sample 1 (S1) to sample 6 (S6)] to investigate the spatial landscape of gene expression. These patients were selected based on previously outlined criteria, with the additional condition that their FFPE blocks had been prepared within the previous month to minimize mRNA degradation. Three 2&#x02009;&#x000d7;&#x02009;2&#x000a0;mm cores were collected from each patient: one from HNSCC, one from SIN, and one from NOM.</p><p id="Par15">Raw read count matrices were normalized to transcripts per kilobase of exome per million mapped reads. Differential gene expression analysis was performed using single-cell RNA sequencing (scRNA-seq) datasets to compare expression patterns across samples from six patients (S1&#x02013;S6) and three clusters. The epithelium was categorized into four clusters: NOM, SIN, HNSCC, and non-evaluable epithelium (excluded epithelium from ICI IHC assessment where apoptosis or necrosis marker positive area, or without nuclei or with necrosis and hemorrhagic area) (categorization is summarized in Online Resource <xref rid="MOESM3" ref-type="media">3</xref>). The analysis was performed using the Seurat package (v4.1.1) following the steps outlined in Online Resource <xref rid="MOESM3" ref-type="media">3</xref>. After processing the transcriptomic data, differentially expressed genes (DEGs) from 18 samples (six NOM, six SIN, and six HNSCC) were normalized, and differential gene expression analysis was conducted using the FindMarkers function. A log-fold change threshold was set to 0.25, and <italic>p</italic>-values&#x02009;&#x0003c;&#x02009;0.05, adjusted using Bonferroni correction, were applied, with a minimum expression percentage (min.pct) of 0.1, to identify the significant DEGs in each cluster. The correlation between mRNA expression and 73&#x02009;&#x02212;&#x02009;10 IHC positivity (TC&#x02009;&#x02265;&#x02009;1%) was identified at log<sub>2</sub> fold change&#x02009;&#x02265;&#x02009;0.25 and p-value&#x02009;&#x0003c;&#x02009;0.05, compared to other clusters in the same cases. Subsequently, KEGG pathway analyses of DEGs between NOM vs. SIN and HNSCC, SIN vs. NOM and HNSCC, and HNSCC vs. NOM and SIN were performed specifically for PD-L1 expression and PD-1 checkpoint pathway in cancer - homo sapiens (human) (hsa05235) and T-cell receptor signaling pathways (hsa04660). Furthermore, hsa04660 of HNSCC was compared with that of NOM (<ext-link ext-link-type="uri" xlink:href="https://www.genome.jp/kegg/">https://www.genome.jp/kegg/</ext-link>; accessed 2024/10/19).</p></sec><sec id="Sec7"><title>Statistical Analyses</title><p id="Par16">Correlations between clinicopathological features and 73&#x02009;&#x02212;&#x02009;10 TC expression levels were determined using Fisher&#x02019;s exact test. The cutoff value for tumor immune activity was calculated as the area under the curve against overall survival (AUC) against OS. A multivariate logistic regression Cox hazard model was constructed to assess the relationship between the predictor variables. If only two factors remained statistically significant, a bivariate analysis was performed. Log-rank tests were used to evaluate OS, disease-specific survival (DSS), and recurrence-free survival (RFS). The association between 73&#x02009;&#x02212;&#x02009;10 TC positive and <italic>CD274</italic> mRNA upregulation was examined using the Pearson correlation coefficient. All statistical analyses were performed using the IBM SPSS Statistics software (v20.0; IBM Corp., Armonk, NY, USA). The significance of mRNA expression was set at log<sub>2</sub> fold-change&#x02009;&#x0003e;&#x02009;0.25 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, and the significance of other analyses was set at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec id="Sec8"><title>Results</title><sec id="Sec9"><title>Demographic and Clinicopathological Characteristics of Patients with 94 HNSCC</title><p id="Par17">The 94 patients comprised 59 males and 35 females, aged between 30 and 87 years (median: 69 years; mean: 68.7&#x02009;&#x000b1;&#x02009;10.9 years) located in the buccal mucosa (<italic>n</italic>&#x02009;=&#x02009;6), gingiva (<italic>n</italic>&#x02009;=&#x02009;26), floor of the mouth (<italic>n</italic>&#x02009;=&#x02009;1), and tongue (<italic>n</italic>&#x02009;=&#x02009;61). The survival time of the patients ranged from 1 to 180 months (median: 42 months; mean: 47.7&#x02009;&#x000b1;&#x02009;39.9 months). During the follow-up period, 41 patients, 28 of whom succumbed to HNSCC, died.</p><p id="Par18">A slight predominance of low TIL was revealed (55%, 52/94) compared to high TIL (45%, 42/94). Notably, the CD4<sup>+</sup> helper T cell response was more prominent than the CD8<sup>+</sup> cytotoxic T cell response [CD4<sup>+</sup> TILs: low 55% (52/94), high 45% (42/94); CD8<sup>+</sup> TILs: low 65% (61/94), high 35% (33/94)]. Overall, HNSCC samples exhibited a predominantly low immune-active status [low immune active: 79% (74/94) vs. high immune active: 21% (20/94)], suggesting T cell exhaustion, particularly of CD8<sup>+</sup> T cells, and potential sensitivity to ICI therapy.</p></sec><sec id="Sec10"><title>Expression Levels of 73&#x02009;&#x02212;&#x02009;10 in NOM, SIN, and HNSCC Cores</title><p id="Par19">Evaluation of TC in NOM, SIN, and HNSCC cores revealed that the number of positive cases of 73&#x02009;&#x02212;&#x02009;10 TC in NOM, SIN, and HNSCC was 3% (2/62), 10% (9/94), and 79% (74/94), respectively (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a, b; Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). To analyze heterogeneous PD-L1 expression in tumors, the expression distribution was examined in superficial and deep invasive front areas. Among the 74 PD-L1-positive HNSCC cases, the majority (88%, 65/74) showed positivity in both areas, while a smaller proportion were positive only in the superficial (7%, 5/74) or deep invasive front areas (5%, 4/74).</p><p id="Par20">
<fig id="Fig1"><label>Fig. 1</label><caption><p>73&#x02009;&#x02212;&#x02009;10 expression in NOM, SIN, and HNSCC. The 73&#x02009;&#x02212;&#x02009;10 staining indicates the absence of NOM (<bold>a</bold>), is focally observed in SIN (<bold>b</bold>), and is positive (TC&#x02009;&#x02265;&#x02009;1%) in both the superficial and deeper cores of HNSCC (b, left), and both negatives (TC&#x02009;&#x0003c;&#x02009;1) in HNSCC cores (b, right). HE, hematoxylin-eosin staining; NOM, normal mucosa; SIN, squamous intraepithelial neoplasm; HNSCC, head and neck squamous cell carcinoma</p></caption><graphic xlink:href="12105_2025_1798_Fig1_HTML" id="d33e448"/></fig>
</p><p id="Par21">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Positive expression cases of 73&#x02009;&#x02212;&#x02009;10 TC in the area of HNSCC cores</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">Expression areas</th><th align="left">positive (%)</th></tr></thead><tbody><tr><td align="left">NOM</td><td align="left" colspan="2">-</td><td align="left">
<bold>3% (2/62)</bold>
</td></tr><tr><td align="left">SIN</td><td align="left" colspan="2">-</td><td align="left">
<bold>10% (9/94)</bold>
</td></tr><tr><td align="left" rowspan="3">HNSCC</td><td align="left">superficial/deep core: (+/+)</td><td align="left">88% (65/74)</td><td align="left" rowspan="3">
<bold>79% (74/94)</bold>
</td></tr><tr><td align="left">superficial/deep core: (+/-)</td><td align="left">7% (5/74)</td></tr><tr><td align="left">superficial/deep core: (-/+)</td><td align="left">5% (4/74)</td></tr></tbody></table><table-wrap-foot><p>NOM, normal oral mucosa; SIN, squamous intraepithelial neoplasm; HNSCC, head and neck squamous cell carcinoma</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>Clinicopathological Analysis of 73&#x02009;&#x02212;&#x02009;10 Expression</title><p id="Par22">The clinicopathological analysis in 94 patients with HNSCC revealed significant associations of 73&#x02009;&#x02212;&#x02009;10 positivity with high CD4<sup>+</sup> TILs expression, pDOI&#x02009;&#x02265;&#x02009;10&#x000a0;mm, and the presence of lymphovascular invasion (all, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), but no significant associations with the expression of TILs, CD8<sup>+</sup> TILs, immune-active status, and other clinicopathological features (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par23">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Association of TC for 73&#x02009;&#x02212;&#x02009;10 IHC clone and clinicopathological features of 94 patients with HNSCC</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="2"/><th align="left" colspan="3">TC for 73&#x02009;&#x02212;&#x02009;10 (HNSCC, <italic>n</italic>&#x02009;=&#x02009;94)</th></tr><tr><th align="left" colspan="2">Clinicopathological features</th><th align="left">Negative</th><th align="left">Positive</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Differentiation</td><td align="left">well/moderately</td><td align="left">12 (22%)</td><td align="left">42 (78%)</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">poorly</td><td align="left">8 (20%)</td><td align="left">32 80%)</td><td align="left"/></tr><tr><td align="left">
<bold>Ly</bold>
</td><td align="left">Negative</td><td align="left">8 (42%)</td><td align="left">11 (58%)</td><td align="left">
<bold><italic>0.02</italic></bold>
</td></tr><tr><td align="left"/><td align="left">Positive</td><td align="left">12 (16%)</td><td align="left">63 (84%)</td><td align="left"/></tr><tr><td align="left">V</td><td align="left">Negative</td><td align="left">5 (33%)</td><td align="left">10 (67%)</td><td align="left">0.3</td></tr><tr><td align="left"/><td align="left">Positive</td><td align="left">15 (19%)</td><td align="left">64 (81%)</td><td align="left"/></tr><tr><td align="left">Pn</td><td align="left">Negative</td><td align="left">5 (25%)</td><td align="left">15 (75%)</td><td align="left">0.76</td></tr><tr><td align="left"/><td align="left">Positive</td><td align="left">15 (20%)</td><td align="left">59 (80%)</td><td align="left"/></tr><tr><td align="left">Invasion pattern</td><td align="left">YK-1,2</td><td align="left">3 (33%)</td><td align="left">6 (67%)</td><td align="left">0.4</td></tr><tr><td align="left"/><td align="left">YK-3,4</td><td align="left">17 (20%)</td><td align="left">68 (80%)</td><td align="left"/></tr><tr><td align="left">
<bold>pDOI</bold>
</td><td align="left">&#x0003c;&#x02009;10&#x000a0;mm</td><td align="left">5 (50%)</td><td align="left">5 (50%)</td><td align="left">
<bold><italic>0.03</italic></bold>
</td></tr><tr><td align="left"/><td align="left">&#x02265;&#x02009;10&#x000a0;mm</td><td align="left">15 (18%)</td><td align="left">69 (82%)</td><td align="left"/></tr><tr><td align="left">pN</td><td align="left">pN0,1</td><td align="left">12 (27%)</td><td align="left">33 (73%)</td><td align="left">0.31</td></tr><tr><td align="left"/><td align="left">pN2,3</td><td align="left">8 (16%)</td><td align="left">41 (84%)</td><td align="left"/></tr><tr><td align="left">pENE</td><td align="left">absence)</td><td align="left">17 (25%)</td><td align="left">52 (75%)</td><td align="left">0.26</td></tr><tr><td align="left"/><td align="left">presence</td><td align="left">3 (12%)</td><td align="left">22 (88%)</td><td align="left"/></tr><tr><td align="left">BUD</td><td align="left">low</td><td align="left">10 (24%)</td><td align="left">31 (76%)</td><td align="left">0.61</td></tr><tr><td align="left"/><td align="left">high</td><td align="left">10 (19%)</td><td align="left">43 (81%)</td><td align="left"/></tr><tr><td align="left">DR</td><td align="left">mature</td><td align="left">4 (17%)</td><td align="left">20 (83%)</td><td align="left">0.77</td></tr><tr><td align="left"/><td align="left">immature</td><td align="left">16 (23%)</td><td align="left">54 (77%)</td><td align="left"/></tr><tr><td align="left">TILs</td><td align="left">low</td><td align="left">13 (21%)</td><td align="left">49 (79%)</td><td align="left">0.23</td></tr><tr><td align="left"/><td align="left">high</td><td align="left">7 (22%)</td><td align="left">25 (78%)</td><td align="left"/></tr><tr><td align="left"><bold>CD4</bold><sup><bold>+</bold></sup>TILs</td><td align="left">low</td><td align="left">17 (33%)</td><td align="left">35 (67%)</td><td align="left">
<bold><italic>&#x0003c;&#x02009;0.001</italic></bold>
</td></tr><tr><td align="left"/><td align="left">High</td><td align="left">3 (7%)</td><td align="left">39 (93%)</td><td align="left"/></tr><tr><td align="left">CD8<sup><bold>+</bold></sup>TILs</td><td align="left">low</td><td align="left">14 (22%)</td><td align="left">47 (78%)</td><td align="left">0.79</td></tr><tr><td align="left"/><td align="left">High</td><td align="left">6 (18%)</td><td align="left">27 (82%)</td><td align="left"/></tr><tr><td align="left">Immune active</td><td align="left">low</td><td align="left">18 (24%)</td><td align="left">56 (76%)</td><td align="left">0.23</td></tr><tr><td align="left"/><td align="left">High</td><td align="left">2 (10%)</td><td align="left">18 (90%)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>BUD, tumor budding; DR, desmoplastic reaction; HNSCC, head and neck squamous cell carcinoma; Ly, lymphovascular invasion; V, vascular invasion; Pn, perineural invasion; pDOI, pathological depth of invasion; pN, pathological lymph node metastasis; pENE, pathological extranodal extension; BUD, budding; DR, desmoplastic reaction; TILs, tumor-infiltrating lymphocytes. <bold>Bold</bold>: <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec12"><title>Prognostic Values of TC for 73&#x02009;&#x02212;&#x02009;10 in Patients with HNSCC</title><p id="Par24">The cox hazard test showed that 73&#x02009;&#x02212;&#x02009;10 positive is the most powerful prognostic indicator of OS (hazard ratio [HR] 5.13, 95% confidence interval [CI] 1.56&#x02013;17.04, <italic>p</italic>&#x02009;=&#x02009;0.007), DSS (5.46; 1.26&#x02013;23.61, 0.023), and RSS (4.49, 1. 60&#x02013;12.57, 0.04) in patients with progressive HNSCCs compared to age, BUD, CD4<sup>+</sup> TILs, CD8<sup>+</sup> TILs, DR, immune activity, pDOI&#x02009;&#x0003e;&#x02009;10&#x000a0;mm, pENE, and pN (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The log-rank test revealed that patients with progressive HNSCC showing 73&#x02009;&#x02212;&#x02009;10 positive had significantly worse OS, DSS, and RFS than those with 73&#x02009;&#x02212;&#x02009;10 negative tumors (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Moreover, low CD4<sup>+</sup> T-cell infiltration, low CD8<sup>+</sup> T-cell infiltration, low numbers of TILs, and immune-desert status were associated with poor prognosis in terms of OS, DSS, and RFS (log-rank test, all <italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05; Online Resource <xref rid="MOESM4" ref-type="media">4</xref>).</p><p id="Par25">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Cox hazard ratio of OS, DSS, and RFS in HNSCC</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="3">OS</th><th align="left" colspan="3">DSS</th><th align="left" colspan="3">RFS</th></tr><tr><th align="left">Multivariate</th><th align="left">HR</th><th align="left">95%CI</th><th align="left"><italic>p</italic>-value</th><th align="left">HR</th><th align="left">95%CI</th><th align="left"><italic>p</italic>-value</th><th align="left">HR</th><th align="left">95%CI</th><th align="left"><italic>p</italic>-value</th></tr></thead><tbody><tr><td align="left">Age&#x02009;&#x0003e;&#x02009;64</td><td align="left">1.34</td><td align="left">0.65&#x02013;2.74</td><td align="left">0.43</td><td align="left">1.60</td><td align="left">0.62&#x02013;4.10</td><td align="left">0.33</td><td align="left">1.47</td><td align="left">0.76&#x02013;2.82</td><td align="left">0.25</td></tr><tr><td align="left">BUD high</td><td align="left">1.55</td><td align="left">0.62&#x02013;3.87</td><td align="left">0.34</td><td align="left">1.18</td><td align="left">0.40&#x02013;3.52</td><td align="left">0.76</td><td align="left">1.34</td><td align="left">0.64&#x02013;2.77</td><td align="left">0.44</td></tr><tr><td align="left">CD4&#x02009;+&#x02009;TILs low</td><td align="left">1.61</td><td align="left">0.46&#x02013;5.63</td><td align="left">0.46</td><td align="left">2.17</td><td align="left">0.43&#x02013;11.04</td><td align="left">0.35</td><td align="left">0.86</td><td align="left">0.28&#x02013;2.65</td><td align="left">0.79</td></tr><tr><td align="left">CD8&#x02009;+&#x02009;TILs low</td><td align="left">1.25</td><td align="left">0.44&#x02013;3.56</td><td align="left">0.68</td><td align="left">0.85</td><td align="left">0.18-4.00</td><td align="left">0.84</td><td align="left">0.91</td><td align="left">0.39&#x02013;2.12</td><td align="left">0.82</td></tr><tr><td align="left">DR immature</td><td align="left">1.17</td><td align="left">0.43&#x02013;3.16</td><td align="left">0.76</td><td align="left">1.74</td><td align="left">0.47&#x02013;6.46</td><td align="left">0.41</td><td align="left">1.32</td><td align="left">0.58-3.00</td><td align="left">0.51</td></tr><tr><td align="left">Immune active low</td><td align="left">1.45</td><td align="left">0.32&#x02013;6.43</td><td align="left">0.63</td><td align="left">2.62</td><td align="left">0.33&#x02013;20.51</td><td align="left">0.36</td><td align="left">2.21</td><td align="left">0.59&#x02013;8.32</td><td align="left">0.24</td></tr><tr><td align="left">pDOI&#x02009;&#x0003e;&#x02009;10&#x000a0;mm</td><td align="left">0.61</td><td align="left">0.18&#x02013;2.04</td><td align="left">0.42</td><td align="left">0.38</td><td align="left">0.08&#x02013;1.71</td><td align="left">0.20</td><td align="left">0.67</td><td align="left">0.23&#x02013;1.97</td><td align="left">0.47</td></tr><tr><td align="left">
<bold>pENE presence</bold>
</td><td align="left">
<bold>3.17</bold>
</td><td align="left">
<bold>1.30&#x02013;7.73</bold>
</td><td align="left">
<bold>0.01</bold>
</td><td align="left">2.82</td><td align="left">0.91&#x02013;8.70</td><td align="left">0.07</td><td align="left">
<bold>2.21</bold>
</td><td align="left">
<bold>1.01&#x02013;4.84</bold>
</td><td align="left">
<bold>0.05</bold>
</td></tr><tr><td align="left">pN presence</td><td align="left">1.50</td><td align="left">0.59&#x02013;3.81</td><td align="left">0.40</td><td align="left">2.36</td><td align="left">0.70&#x02013;7.94</td><td align="left">0.17</td><td align="left">1.14</td><td align="left">0.52&#x02013;2.48</td><td align="left">0.74</td></tr><tr><td align="left">
<bold>TC for 73&#x02009;&#x02212;&#x02009;10&#x02009;&#x02265;&#x02009;1</bold>
</td><td align="left">
<bold>8.66</bold>
</td><td align="left">
<bold>2.33&#x02013;32.27</bold>
</td><td align="left">
<bold>0.001</bold>
</td><td align="left">
<bold>14.48</bold>
</td><td align="left">
<bold>2.58&#x02013;81.27</bold>
</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">
<bold>5.71</bold>
</td><td align="left">
<bold>1.95&#x02013;16.70</bold>
</td><td align="left">
<bold>0.001</bold>
</td></tr><tr><td align="left">
<bold>Bivariate</bold>
</td><td align="left">HR</td><td align="left">95%CI</td><td align="left"><italic>p</italic>-value</td><td align="left">HR</td><td align="left">95%CI</td><td align="left"><italic>p</italic>-value</td><td align="left">HR</td><td align="left">95%CI</td><td align="left"><italic>p</italic>-value</td></tr><tr><td align="left">pENE presence</td><td align="left">4.23</td><td align="left">2.22&#x02013;8.07</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">4.78</td><td align="left">2.19&#x02013;10.43</td><td align="left">&#x0003c;&#x02009;0.001</td><td align="left">2.39</td><td align="left">1.32&#x02013;4.31</td><td align="left">0.004</td></tr><tr><td align="left">
<bold>73&#x02009;&#x02212;&#x02009;10 positive (TC&#x02009;&#x02265;&#x02009;1%)</bold>
</td><td align="left">
<bold>5.16</bold>
</td><td align="left">
<bold>1.56&#x02013;17.04</bold>
</td><td align="left">
<bold>0.007</bold>
</td><td align="left">
<bold>5.46</bold>
</td><td align="left">
<bold>1.26&#x02013;23.61</bold>
</td><td align="left">
<bold>0.023</bold>
</td><td align="left">
<bold>4.49</bold>
</td><td align="left">
<bold>1.60-12.57</bold>
</td><td align="left">
<bold>0.004</bold>
</td></tr></tbody></table><table-wrap-foot><p>OS: overall survival, DSS: disease-specific survival, RFS: recurrence-free survival, HR, Hazard ratio, CI: confidence interval, BUD: budding, TILs: tumor-infiltrating lymphocytes; DR, desmoplastic reaction; pDOI: pathological depth of invasion, pENE: pathological extranodal extension, pN: pathological lymph node metastasis; TC, tumor cell score. <bold>Bold</bold>: <italic>p</italic> value&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap>
</p><p id="Par26">
<fig id="Fig2"><label>Fig. 2</label><caption><p>OS, DSS, and RFS of HNSCC evaluated using 73&#x02009;&#x02212;&#x02009;10 detected PD-L1. OS, overall survival; DSS, disease-specific survival; RFS, recurrence-free survival; HNSCC, head and neck squamous cell carcinoma; TC, tumor cell score; CI, confidence interval</p></caption><graphic xlink:href="12105_2025_1798_Fig2_HTML" id="d33e1392"/></fig>
</p></sec><sec id="Sec13"><title>Associations of 73&#x02009;&#x02212;&#x02009;10 Expression and <italic>CD274</italic> mRNA and Protein Distributions in HNSCC Tissue</title><p id="Par27"><italic>CD274</italic> (PD-L1) mRNA expression was further examined on Visium ST spots from NOM, SIN, and HNSCC samples to determine whether 73&#x02009;&#x02212;&#x02009;10 IHC expression reflected underlying molecular features.</p><p id="Par28">The expression of <italic>CD274</italic> mRNA and the 73&#x02009;&#x02212;&#x02009;10 IHC staining are shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, b, and their overexpression distributions matched. <italic>CD274</italic> was significantly upregulated in neoplasms compared to NOM groups, especially in HNSCC groups (log<sub>2</sub> fold&#x02009;&#x0003e;&#x02009;0.25 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, b). Furthermore, it was significantly upregulated in core of HNSCC (100%) and SIN (66%) compared to that in the paired NOM (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c). Five samples (88%) exhibited the highest <italic>CD274</italic> expression in HNSCC cores among the three groups (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>c and Online Resource <xref rid="MOESM3" ref-type="media">5</xref>). Immunohistochemically, a higher 73-10-positive expression frequency was observed in HNSCC (100%) than in SIN and NOM (each 16%), which was consistent with the mRNA expression results. The coefficients of correlation between the negative or positive status for <italic>CD274</italic> and 73&#x02009;&#x02212;&#x02009;10 were 83% for NOM, 50% for SIN, and 100% for HNSCC, with a significant correlation (<italic>r</italic>&#x02009;=&#x02009;0.58, 95% CI: 0.148&#x02013;0.82, <italic>p</italic>&#x02009;=&#x02009;0.01, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>d).</p><p id="Par29">
<fig id="Fig3"><label>Fig. 3</label><caption><p>73&#x02009;&#x02212;&#x02009;10 detected PD-L1 and <italic>CD274</italic> mRNA expression. Verification of PD-L1 expression at mRNA and protein levels in NOM, SIN, and HNSCC (<bold>a</bold>, <bold>b</bold>); green arrows indicate PD-L1 and <italic>CD274</italic> mRNA overexpression area. PD-L1 and <italic>CD274</italic> mRNA expression in all six cases (<bold>c</bold>). Correlation coefficient between 73&#x02009;&#x02212;&#x02009;10 detected PD-L1 and <italic>CD274</italic> mRNA expression (<bold>d</bold>). PD-L1, Programmed death-ligand 1; HE, hematoxylin and eosin; IHC, immunohistochemistry; HNSCC, head and neck squamous cell carcinoma; SIN, squamous intraepithelial neoplasia; NOM, normal oral mucosa; S, sample; CI, confidence interval</p></caption><graphic xlink:href="12105_2025_1798_Fig3_HTML" id="d33e1483"/></fig>
</p></sec><sec id="Sec14"><title>Pathway Analysis of PD-L1 in HNSCC, SIN, and NOM</title><p id="Par30">Based on the correlation between 73&#x02009;&#x02212;&#x02009;10 IHC and <italic>CD274</italic> expression in HNSCC, SIN, and NOM, pathway analysis was performed using Visium-derived DEGs to elucidate the mechanisms driving poor prognosis in PD-L1-positive HNSCC cases.</p><p id="Par31">A total of 94 DEGs were detected in 18 cores (6 cores of NOM, 6 cores of SIN, and 6 cores of HNSCC) obtained from the PD-L1-related signaling pathway in cancer cells (hsa05235). Pathway analysis revealed that most genes included in has05235 were upregulated in HNSCC (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, Online Resource <xref rid="MOESM3" ref-type="media">6</xref>). Among the 49 significant DEGs in the NOM, SIN, and HNSCC groups (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>b, Online Resource <xref rid="MOESM3" ref-type="media">6</xref>), the hypoxia-inducible factor-1 alpha (HIF-1&#x003b1;) and interferon-gamma (IFN-&#x003b3;) pathways were significantly upregulated in HNSCC compared to NOM and SIN, with further upregulation observed relative to SIN (Online Resource <xref rid="MOESM3" ref-type="media">7</xref>). Other signaling pathways, such as the toll-like receptor, PI3K-Akt, and MAPK pathways, were also activated in HNSCC and SIN; however, some downstream genes were downregulated compared with NOM.</p><p id="Par32">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Gene expression in PD-L1-related and T-cell receptor pathways in cancer cells. Log<sub>2</sub> enhanced heat maps of PD-L1 related genes in six HNSCC, six SIN, and six NOM samples (<bold>a</bold>). Comparison of the three groups (<bold>b</bold>). PD-L1-related pathways in cancer cells compared to NOM, SIN, and HNSCC (<bold>c</bold>). T-cell receptor signaling in HNSCC compared to NOM (<bold>d</bold>). PD-L1, Programmed death-ligand 1; HNSCC, head and neck squamous cell carcinoma; SIN, squamous intraepithelial neoplasia; NOM, normal oral mucosa; HIF-1&#x003b1;, hypoxia-inducible factor-1 alpha; IFN-&#x003b3;, interferon-gamma</p></caption><graphic xlink:href="12105_2025_1798_Fig4_HTML" id="d33e1532"/></fig>
</p></sec><sec id="Sec15"><title>Pathway Analysis of PD-L1 Check Point Pathway in T-cells Compared To HNSCC and NOM</title><p id="Par33">In the epithelium of HNSCC and SIN compared to NOM, Hsa05235 analysis showed upregulation of <italic>CD274</italic> (PD-L1) and its related pathways; however, no upregulation of <italic>PDCD1</italic> (PD-1) on T-cells was observed. Therefore, the T-cell receptor signaling pathway (hsa04660) was further analyzed, revealing that neither <italic>PDCD1</italic> (PD-1) nor <italic>CTLA4</italic>, the ICIs target ligands, were upregulated in HNSCC, as also confirmed by ST (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>d, Online Resource <xref rid="MOESM3" ref-type="media">7</xref>) and SIN (data not shown) compared with NOM. However, the downstream signaling of <italic>PDCD1</italic>, including genes such as <italic>SHIP1/2</italic>, <italic>BATF</italic>, and <italic>PI3K</italic>, was upregulated, suggesting that pathways beyond <italic>PDCD1</italic> may also contribute to T cell suppression.</p><p id="Par34">Among the T-cell markers, only the expression of <italic>CD4</italic> was significantly upregulated in HNSCC compared to that in NOM, and its downstream pathway, the calcium signaling pathway, was also upregulated. However, no significant differences were observed in the expression levels of <italic>CD3</italic>, <italic>CD8</italic>, or <italic>CD28</italic>. These results suggest that PD-L1 may be a more effective ICIs target than PD-1 and CTLA4, with CD4<sup>+</sup> T-cells playing a key role in the tumor immune response in progressive HNSCC.</p></sec></sec><sec id="Sec16"><title>Discussion</title><p id="Par35">In this study, PD-L1 expression in HNSCC was evaluated using the 73&#x02009;&#x02212;&#x02009;10 IHC clone, revealing that 79% of cases were PD-L1 positive (TC&#x02009;&#x02265;&#x02009;1%) and associated with poor prognosis owing to low CD4<sup>+</sup> T-cell infiltration. This PD-L1 upregulation may have induced by activation of HIF-1&#x003b1; and IFN&#x003b3; cascades during HNSCC carcinogenesis. Notably, significant 73-10-detected PD-L1 protein expression was observed in the tumor cells of invasive HNSCC compared to the epithelium of SIN and NOM, with relatively uniform expression throughout the tumor and high concordance with <italic>CD274</italic> mRNA expression in terms of both spatial distribution and expression levels. However, neither <italic>PDCD1</italic> (PD-1) nor <italic>CTLA4</italic> were upregulated. These novel aspects collectively support the clinical utility of evaluation using the 73&#x02009;&#x02212;&#x02009;10 IHC-detected PD-L1 expression with CD4<sup>+</sup> T-cells playing a key role in the tumor immune response in progressive HNSCC.</p><p id="Par36">First, we evaluated the potential of 73&#x02009;&#x02212;&#x02009;10 IHC to detect whether PD-L1 expression could be used as a target of ICIs and expand the pool of eligible patients with HNSCC for ICIs. The 73&#x02009;&#x02212;&#x02009;10 TC&#x02009;&#x02265;&#x02009;1% was observed in 79% of patients with HNSCC, which consistent with previous study, reporting 73&#x02009;&#x02212;&#x02009;10 TC&#x02009;&#x02265;&#x02009;1% in 78% of patients with progressive HNSCC [<xref ref-type="bibr" rid="CR15">15</xref>]. These positive rate notably higher than the 40&#x02013;60% observed in previous evaluations of HNSCC using other PD-L1/PD-1 clones [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR18">18</xref>]. On lung and bladder cancers assessed with 73&#x02009;&#x02212;&#x02009;10 clone showed higher sensitivity than other clones, likely because of its ability to recognize the intracellular domain of PD-L1, whereas other clones target the extracellular domain [<xref ref-type="bibr" rid="CR9">9</xref>]. Furthermore, a high concordance in PD-L1 expression between superficial and deep tumor cores was observed, in line with a previous report on the high concordance between biopsy and resection samples [<xref ref-type="bibr" rid="CR19">19</xref>]. These findings suggest that the 73&#x02009;&#x02212;&#x02009;10 TC&#x02009;&#x02265;&#x02009;1% evaluation method may offer a highly sensitive and specific approach to identifying patients who could benefit from ICIs. In other words, with the potential to address concerns about tumor heterogeneity associated with sampling sites, this method could improve biopsy suitability and help expand the pool of patients with HNSCC eligible for immunotherapy.</p><p id="Par37">Moreover, the 73&#x02009;&#x02212;&#x02009;10 TC&#x02009;&#x02265;&#x02009;1% evaluation method demonstrated strong prognostic value. The 73&#x02009;&#x02212;&#x02009;10 TC&#x02009;&#x02265;&#x02009;1% status was the most significant independent prognostic factor for OS, DSS, and PFS in patients with HNSCC, outperforming the other clinicopathological features. These findings are consistent with results from a Phase I clinical trial [<xref ref-type="bibr" rid="CR15">15</xref>], which also used a 73&#x02009;&#x02212;&#x02009;10 TC&#x02009;&#x02265;&#x02009;1% cutoff to evaluate the outcomes. Furthermore, the association between 73&#x02009;&#x02212;&#x02009;10 positivity and high CD4<sup>+</sup> TILs in progressive HNSCC aligns with the mRNA expression data related to the PD-L1 signaling pathway. In some cancers including HNSCC, intratumoral CD4<sup>+</sup> T cells exhibit cytotoxic phenotypes capable of directly killing cancer cells, similar to CD8<sup>+</sup> T-cells, while performing helper functions [<xref ref-type="bibr" rid="CR24">24</xref>]. However, the HNSCC cohort exhibited a predominantly low immune-active status in most samples (80%), and no correlation was found between CD8<sup>+</sup> T cell infiltration and PD-L1 expression. Despite this overall low immune activity, this study, fortified by a large sample size comparable to or exceeding those of previous reports, revealed through signaling pathway analysis a strong association between CD4<sup>+</sup> TILs and PD-L1 expression. Furthermore, the minimal influence of tumor heterogeneity on PD-L1 is reinforced. These results highlight the novel insight that CD4<sup>+</sup> T cells may play a more critical immunomodulatory role in HNSCC.</p><p id="Par38">The findings also revealed that 73&#x02009;&#x02212;&#x02009;10 IHC expression and distribution corresponded to <italic>CD274</italic> (PD-L1) mRNA expression, showing upregulation in the epithelium of invasive HNSCC compared to NOM and SIN. This suggests their involvement in PD-L1 expression during carcinogenesis of progressive HNSCC. Previous studies examining the relationship between PD-L1 mRNA and protein expression in various cancer cell lines, including HNSCC cells, have shown similar results [<xref ref-type="bibr" rid="CR25">25</xref>]. Furthermore, the present study provides novel evidence that 73&#x02009;&#x02212;&#x02009;10 IHC detecting PD-L1 expression corresponds to that of mRNA at the spatial distribution level, with upregulation observed in the order of HNSCC, SIN, and NOM in all six cases. These findings reveal that 73-10-detected PD-L1 plays an important role in the tumor microenvironment during the malignant transformation process and that 73&#x02009;&#x02212;&#x02009;10 IHC as a visually accessible method for assessing PD-L1-related pathway activation.</p><p id="Par39">Pathway analysis revealed that the HIF-1&#x003b1; and IFN&#x003b3; pathways are particularly critical for PD-L1 upregulation in HNSCCs. Furthermore, neither <italic>PDCD1</italic> (PD-1) nor <italic>CTLA4</italic>, the ICI target ligands, were upregulated. These results suggest that PD-L1 may be a more effective ICI target than PD-1 and CTLA4. In multiple cancers, including HNSCC, HIF-1&#x003b1; translocates to the nucleus to promote malignant cell survival [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Additionally, T-cell products, including IFN-&#x003b3;, activate the IFN-&#x003b3; signaling pathway, which further upregulates PD-L1 expression in tumor cells [<xref ref-type="bibr" rid="CR28">28</xref>]. The poor prognostic factors of HNSCC include severe hypoxia, elevated IFN-&#x003b3; levels, and a suppressed immune response [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. The findings of the present study align with these observations, suggesting that HIF-1&#x003b1; and IFN&#x003b3; pathways may contribute to the poor prognosis of 73&#x02009;&#x02212;&#x02009;10 IHC-positive HNSCC. In addition, <italic>PDCD1</italic> (PD-1) and <italic>CTLA4</italic> were not significantly upregulated in HNSCC compared with NOM and SIN, despite the upregulation of <italic>CD274</italic> (PD-L1). Similar observations of PD-1 expression in SIN and HNSCC compared to NOM have also been reported [<xref ref-type="bibr" rid="CR30">30</xref>]. In patients with HNSCC, IHC using 22&#x000a0;C-3 and 28&#x02009;&#x02212;&#x02009;8 clone are approved as companion diagnostic tools for PD-1 expression. Conversely, anti-CTLA-4 antibodies, which target activated T cells, especially CD4 <sup>+</sup> regulatory T-cells, have not yet been approved for the treatment of HNSCC [<xref ref-type="bibr" rid="CR31">31</xref>]. Considering that PD-L1 inhibition is an established approach in clinical settings, our findings suggested that PD-L1 targeting therapy or a combination therapy targeting HIF-1&#x003b1; and IFN-&#x003b3; might represent a promising novel strategy for treating HNSCC.</p><p id="Par40">This study has several limitations. First, the single-institution design and lack of post-treatment HNSCC samples limit the generalizability of our findings. Additionally, excluding HPV-associated HNSCCs may limit the applicability of our results. ICIs are more effective in HPV-associated HNSCC owing to higher PD-L1 expression from HPV oncoproteins and T-cell exhaustion [<xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR35">35</xref>], suggesting PD-L1 evaluation with the 73&#x02009;&#x02212;&#x02009;10 clone is particularly useful for this subtype. Despite the multi-core TMA approach, 10% of HNSCC cases still exhibited heterogeneous 73&#x02009;&#x02212;&#x02009;10 staining, highlighting the need to consider re-biopsy in cases with negative results. Furthermore, to enhance generalizability and clinical applicability, 73&#x02009;&#x02212;&#x02009;10 expression should be evaluated using the Combined Positive Score, as this scoring method is standard for companion IHC diagnostics in HNSCC. We are preparing a separate manuscript that includes these results for publication in the near future. Future studies should include a larger cohort of patients, both with and without prior treatment, to compare treatment outcomes between the evaluation systems using 73&#x02009;&#x02212;&#x02009;10 and other PD-L1 clones. Future studies are needed to clarify the potential confounding factor of patients with high PD-L1 expression receiving ICI therapy and experiencing improved outcomes between the evaluation systems including other PD-L1 clones and other methods (e.g., CPS, cut off: 0, &#x02265;&#x02009;1+, &#x02265;&#x02009;20+), and include patients receiving ICI therapy.</p></sec><sec id="Sec17"><title>Conclusion</title><p id="Par41">The 73&#x02009;&#x02212;&#x02009;10 IHC represents a highly sensitive and specific approach for detecting PD-L1 in HNSCC, with minimal concerns about tumor heterogeneity and sampling bias. Our findings suggest that this method could expand the pool of eligible patients with HNSCC who are likely to benefit from ICI therapy. Further studies are needed to validate the clinical utility of the 73&#x02009;&#x02212;&#x02009;10 clone and its potential as a predictive biomarker for ICI therapy in HNSCC.</p></sec><sec id="Sec18" sec-type="supplementary-material"><title>Electronic Supplementary Material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12105_2025_1798_MOESM1_ESM.xlsx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12105_2025_1798_MOESM2_ESM.xlsx"><caption><p>Supplementary Material 2</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="12105_2025_1798_MOESM3_ESM.xlsx"><caption><p>Supplementary Material 3</p></caption></media></supplementary-material>
</p><p>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="12105_2025_1798_MOESM4_ESM.docx"><caption><p>Supplementary Material 4</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Yoko Tokuyama for performing CD3, CD4, and 73-10 immunohistochemical staining and Takehiro Jinbo normalizing the differentially expressed genes. This study received no funding from any governmental or private institution. We thank Yoko Tokuyama for performing CD3, CD4, and 73-10 immunohistochemical staining and Takehiro Jinbo for normalizing the differentially expressed genes.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>All authors contributed to the conception and design of the study. YN performed the computations, evaluated the histological risk factors, and collected the clinical information for this study. NA and TN supervised this study and developed the theory. HI collected clinical information, and supervised this study. KT conceived the idea, developed the theory, and supervised this study. YN wrote the first draft of the manuscript, and all authors commented on later versions. All authors have read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study received no funding from any governmental or private institution.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics Approval and Consent to Participate</title><p id="Par42">This study was conducted in accordance with the principles of the Declaration of Helsinki and approved by the Institutional Review Board of Kansai Medical University Hospital (approval number 2020289). Informed consent was obtained from the patients who could withdraw from participation using the opt-out methodology. The retrospective design of the study did not pose any new risks to the participants.</p></notes><notes id="FPar2"><title>Consent for Publication</title><p id="Par43">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing Interests</title><p id="Par44">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Barsouk</surname><given-names>A</given-names></name><name><surname>Aluru</surname><given-names>JS</given-names></name><name><surname>Rawla</surname><given-names>P</given-names></name><name><surname>Saginala</surname><given-names>K</given-names></name><name><surname>Barsouk</surname><given-names>A</given-names></name></person-group><article-title>Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma</article-title><source>Med Sci (Basel)</source><year>2023</year><volume>11</volume><issue>2</issue><fpage>42</fpage><pub-id pub-id-type="doi">10.3390/medsci11020042</pub-id><pub-id pub-id-type="pmid">37367741</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A (2023) Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel) 11(2):42. 10.3390/medsci11020042<pub-id pub-id-type="pmid">37367741</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferris</surname><given-names>RL</given-names></name><name><surname>Blumenschein</surname><given-names>G</given-names></name><name><surname>Fayette</surname><given-names>J</given-names></name><etal/></person-group><article-title>Nivolumab for recurrent squamous-cell carcinoma of the head and neck</article-title><source>N Engl J Med</source><year>2016</year><volume>375</volume><fpage>1856</fpage><lpage>1867</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1602252</pub-id><pub-id pub-id-type="pmid">27718784</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Ferris RL, Blumenschein G, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856&#x02013;1867. 10.1056/NEJMoa1602252<pub-id pub-id-type="pmid">27718784</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Chalker</surname><given-names>C</given-names></name><name><surname>Voutsinas</surname><given-names>JM</given-names></name><name><surname>Wu</surname><given-names>QV</given-names></name><etal/></person-group><article-title>Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients</article-title><source>Cancer Med</source><year>2022</year><volume>11</volume><fpage>4104</fpage><lpage>4111</lpage><pub-id pub-id-type="doi">10.1002/cam4.4722</pub-id><pub-id pub-id-type="pmid">35349227</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Chalker C, Voutsinas JM, Wu QV et al (2022) Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients. Cancer Med 11:4104&#x02013;4111. 10.1002/cam4.4722<pub-id pub-id-type="pmid">35349227</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><etal/></person-group><article-title>The current advances and future directions of PD-1/PD-L1 Blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy</article-title><source>Int Immunopharmacol</source><year>2023</year><volume>120</volume><fpage>110329</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2023.110329</pub-id><pub-id pub-id-type="pmid">37207445</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Chen Y, Ding X, Bai X et al (2023) The current advances and future directions of PD-1/PD-L1 Blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy. Int Immunopharmacol 120:110329. 10.1016/j.intimp.2023.110329<pub-id pub-id-type="pmid">37207445</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Nocini</surname><given-names>R</given-names></name><name><surname>Vianini</surname><given-names>M</given-names></name><name><surname>Girolami</surname><given-names>I</given-names></name><etal/></person-group><article-title>PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to bedside</article-title><source>Clin Exp Dent Res</source><year>2022</year><volume>8</volume><fpage>690</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1002/cre2.590</pub-id><pub-id pub-id-type="pmid">35593124</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Nocini R, Vianini M, Girolami I et al (2022) PD-L1 in oral squamous cell carcinoma: A key biomarker from the laboratory to bedside. Clin Exp Dent Res 8:690&#x02013;698. 10.1002/cre2.590<pub-id pub-id-type="pmid">35593124</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>LQM</given-names></name></person-group><article-title>Head and neck Cancer</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>1</issue><fpage>60</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1715715</pub-id><pub-id pub-id-type="pmid">31893516</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Chow LQM (2020) Head and neck Cancer. N Engl J Med 382(1):60&#x02013;72. 10.1056/NEJMra1715715<pub-id pub-id-type="pmid">31893516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR (2020) Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6(1):92. 10.1038/s41572-020-00224-3. [Erratum in: Nat Rev Dis Primers 2023; 9(1):4. 10.1038/s41572-023-00418-5]</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Ribbat-Idel</surname><given-names>J</given-names></name><name><surname>Dressler</surname><given-names>FF</given-names></name><name><surname>Krupar</surname><given-names>R</given-names></name><etal/></person-group><article-title>Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma</article-title><source>Front Med (Lausanne)</source><year>2021</year><volume>8</volume><fpage>640515</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.640515</pub-id><pub-id pub-id-type="pmid">33987192</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ribbat-Idel J, Dressler FF, Krupar R et al (2021) Performance of different diagnostic PD-L1 clones in head and neck squamous cell carcinoma. Front Med (Lausanne) 8:640515. 10.3389/fmed.2021.640515<pub-id pub-id-type="pmid">33987192</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>MS</given-names></name><name><surname>Kerr</surname><given-names>KM</given-names></name><name><surname>Kockx</surname><given-names>M</given-names></name><etal/></person-group><article-title>PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project</article-title><source>J Thorac Oncol</source><year>2018</year><volume>13</volume><fpage>1302</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.05.013</pub-id><pub-id pub-id-type="pmid">29800747</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Tsao MS, Kerr KM, Kockx M et al (2018) PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 13:1302&#x02013;1311. 10.1016/j.jtho.2018.05.013<pub-id pub-id-type="pmid">29800747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>J</given-names></name><name><surname>Ohe</surname><given-names>C</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><etal/></person-group><article-title>PD-L1 expression and clinicopathological factors in renal cell carcinoma: a comparison of antibody clone 73&#x02013;&#x02009;10 with clone 28&#x02013;&#x02009;8</article-title><source>Anticancer Res</source><year>2021</year><volume>41</volume><fpage>4577</fpage><lpage>4586</lpage><pub-id pub-id-type="doi">10.21873/anticanres.15271</pub-id><pub-id pub-id-type="pmid">34475086</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Ikeda J, Ohe C, Yoshida T et al (2021) PD-L1 expression and clinicopathological factors in renal cell carcinoma: a comparison of antibody clone 73&#x02013;&#x02009;10 with clone 28&#x02013;&#x02009;8. Anticancer Res 41:4577&#x02013;4586. 10.21873/anticanres.15271<pub-id pub-id-type="pmid">34475086</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Grote HJ, Feng Z, Schlichting M et al (2020) Programmed death-ligand 1 immunohistochemistry assay comparison studies in NSCLC: characterization of the 73&#x02013;&#x02009;10 assay. J Thorac Oncol. 2020;15:1306&#x02013;1316. 10.1016/j.jtho.2020.04.013</mixed-citation></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Wankhede</surname><given-names>D</given-names></name><name><surname>Hofman</surname><given-names>P</given-names></name><name><surname>Grover</surname><given-names>S</given-names></name></person-group><article-title>PD-1/PD-L1 inhibitors in treatment-na&#x000ef;ve, advanced non-small cell lung cancer patients with &#x0003c;&#x02009;1% PD-L1 expression: a meta-analysis of randomized controlled trials</article-title><source>J Cancer Res Clin Oncol</source><year>2023</year><volume>149</volume><issue>5</issue><fpage>2179</fpage><lpage>2189</lpage><pub-id pub-id-type="doi">10.1007/s00432-022-04286-6</pub-id><pub-id pub-id-type="pmid">35984491</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Wankhede D, Hofman P, Grover S (2023) PD-1/PD-L1 inhibitors in treatment-na&#x000ef;ve, advanced non-small cell lung cancer patients with &#x0003c;&#x02009;1% PD-L1 expression: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 149(5):2179&#x02013;2189. 10.1007/s00432-022-04286-6<pub-id pub-id-type="pmid">35984491</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Gajate</surname><given-names>P</given-names></name><name><surname>Torres-Jim&#x000e9;nez</surname><given-names>J</given-names></name><name><surname>Bueno-Bravo</surname><given-names>C</given-names></name><name><surname>Cou&#x000f1;ago</surname><given-names>F</given-names></name></person-group><article-title>Practice change in the management of metastatic urothelial carcinoma after ASCO 2020</article-title><source>World J Clin Oncol</source><year>2020</year><volume>11</volume><issue>12</issue><fpage>976</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.5306/wjco.v11.i12.976</pub-id><pub-id pub-id-type="pmid">33437659</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Gajate P, Torres-Jim&#x000e9;nez J, Bueno-Bravo C, Cou&#x000f1;ago F (2020) Practice change in the management of metastatic urothelial carcinoma after ASCO 2020. World J Clin Oncol 11(12):976&#x02013;982. 10.5306/wjco.v11.i12.976<pub-id pub-id-type="pmid">33437659</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Dirix</surname><given-names>LY</given-names></name><name><surname>Takacs</surname><given-names>I</given-names></name><name><surname>Jerusalem</surname><given-names>G</given-names></name><etal/></person-group><article-title>Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study</article-title><source>Breast Cancer Res Treat</source><year>2018</year><volume>167</volume><issue>3</issue><fpage>671</fpage><lpage>686</lpage><pub-id pub-id-type="doi">10.1007/s10549-017-4537-5</pub-id><pub-id pub-id-type="pmid">29063313</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Dirix LY, Takacs I, Jerusalem G et al (2018) Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study. Breast Cancer Res Treat 167(3):671&#x02013;686. 10.1007/s10549-017-4537-5<pub-id pub-id-type="pmid">29063313</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Cho BC, Daste A, Ravaud A et al (2020) Bintrafusp alfa, a bifunctional fusion protein targeting TGF-&#x003b2; and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer 8(2):e000664. <pub-id pub-id-type="doi">10.1136/jitc-2020-000664</pub-id>. [Erratum in: J Immunother Cancer. 2020;8(2):e000664corr1. 10.1136/jitc-2020-000664</mixed-citation></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>de Ruiter</surname><given-names>EJ</given-names></name><name><surname>Mulder</surname><given-names>FJ</given-names></name><name><surname>Koomen</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)</article-title><source>Mod Pathol</source><year>2021</year><volume>34</volume><issue>6</issue><fpage>1125</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1038/s41379-020-0644-7</pub-id><pub-id pub-id-type="pmid">32759978</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">de Ruiter EJ, Mulder FJ, Koomen BM et al (2021) Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC). Mod Pathol 34(6):1125&#x02013;1132. 10.1038/s41379-020-0644-7<pub-id pub-id-type="pmid">32759978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Blatt</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>M</given-names></name><name><surname>Rump</surname><given-names>C</given-names></name><name><surname>Zimmer</surname><given-names>S</given-names></name><name><surname>Sagheb</surname><given-names>K</given-names></name><name><surname>K&#x000fc;nzel</surname><given-names>J</given-names></name></person-group><article-title>Differences in PD-L1 expression between oral and oropharyngeal squamous cell carcinoma</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><issue>5</issue><fpage>e0269136</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0269136</pub-id><pub-id pub-id-type="pmid">35622885</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Blatt S, Kr&#x000fc;ger M, Rump C, Zimmer S, Sagheb K, K&#x000fc;nzel J (2022) Differences in PD-L1 expression between oral and oropharyngeal squamous cell carcinoma. PLoS ONE 17(5):e0269136. 10.1371/journal.pone.0269136<pub-id pub-id-type="pmid">35622885</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Jeong</surname><given-names>JS</given-names></name><name><surname>Jo</surname><given-names>U</given-names></name><name><surname>Choi</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>KJ</given-names></name><name><surname>Song</surname><given-names>JS</given-names></name></person-group><article-title>Comparison of PD-L1 assays in head and neck carcinoma</article-title><source>Pathology</source><year>2024</year><volume>56</volume><issue>7</issue><fpage>969</fpage><lpage>981</lpage><pub-id pub-id-type="doi">10.1016/j.pathol.2024.06.006</pub-id><pub-id pub-id-type="pmid">39261273</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Jeong JS, Jo U, Choi G, Song H, Cho KJ, Song JS (2024) Comparison of PD-L1 assays in head and neck carcinoma. Pathology 56(7):969&#x02013;981. 10.1016/j.pathol.2024.06.006<pub-id pub-id-type="pmid">39261273</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini-Spaltro</surname><given-names>A</given-names></name><name><surname>Limarzi</surname><given-names>F</given-names></name><name><surname>Gaudio</surname><given-names>M</given-names></name><name><surname>Calpona</surname><given-names>S</given-names></name><name><surname>Meccariello</surname><given-names>G</given-names></name></person-group><article-title>PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis</article-title><source>Virchows Arch</source><year>2022</year><volume>481</volume><issue>1</issue><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s00428-022-03322-7</pub-id><pub-id pub-id-type="pmid">35420378</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Ambrosini-Spaltro A, Limarzi F, Gaudio M, Calpona S, Meccariello G (2022) PD-L1 expression in head and neck carcinoma by combined positive score: a comparison among preoperative biopsy, tumor resection, and lymph node metastasis. Virchows Arch 481(1):93&#x02013;99. 10.1007/s00428-022-03322-7<pub-id pub-id-type="pmid">35420378</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Barkley</surname><given-names>D</given-names></name><name><surname>Fran&#x000e7;a</surname><given-names>GS</given-names></name><etal/></person-group><article-title>Exploring tissue architecture using Spatial transcriptomics</article-title><source>Nature</source><year>2021</year><volume>596</volume><issue>7871</issue><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03634-9</pub-id><pub-id pub-id-type="pmid">34381231</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Rao A, Barkley D, Fran&#x000e7;a GS et al (2021) Exploring tissue architecture using Spatial transcriptomics. Nature 596(7871):211&#x02013;220. 10.1038/s41586-021-03634-9<pub-id pub-id-type="pmid">34381231</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Ueno H, Kanemitsu Y, Sekine S et al (2017) Desmoplastic pattern at the tumor front defines poor-prognosis subtypes of colorectal cancer. Am J Surg Pathol 41(11):1506&#x02013;1512. 10.1097/PAS.0000000000000946. PMID: 28877064</mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Lugli</surname><given-names>A</given-names></name><name><surname>Kirsch</surname><given-names>R</given-names></name><name><surname>Ajioka</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Recommendations for reporting tumor budding in colorectal cancer based on the international tumor budding consensus conference (ITBCC) 2016</article-title><source>Mod Pathol</source><year>2017</year><volume>30</volume><issue>9</issue><fpage>1299</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2017.46</pub-id><pub-id pub-id-type="pmid">28548122</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Lugli A, Kirsch R, Ajioka Y et al (2017) Recommendations for reporting tumor budding in colorectal cancer based on the international tumor budding consensus conference (ITBCC) 2016. Mod Pathol 30(9):1299&#x02013;1311. 10.1038/modpathol.2017.46<pub-id pub-id-type="pmid">28548122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Heikkinen</surname><given-names>I</given-names></name><name><surname>Bello</surname><given-names>IO</given-names></name><name><surname>Wahab</surname><given-names>A</given-names></name><etal/></person-group><article-title>Assessment of tumor-infiltrating lymphocytes predicts the behavior of early-stage oral tongue cancer</article-title><source>Am J Surg Pathol</source><year>2019</year><volume>43</volume><issue>10</issue><fpage>1392</fpage><lpage>1396</lpage><pub-id pub-id-type="doi">10.1097/PAS.0000000000001323</pub-id><pub-id pub-id-type="pmid">31290758</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Heikkinen I, Bello IO, Wahab A et al (2019) Assessment of tumor-infiltrating lymphocytes predicts the behavior of early-stage oral tongue cancer. Am J Surg Pathol 43(10):1392&#x02013;1396. 10.1097/PAS.0000000000001323<pub-id pub-id-type="pmid">31290758</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Cachot</surname><given-names>A</given-names></name><name><surname>Bilous</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>YC</given-names></name><etal/></person-group><article-title>Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer</article-title><source>Sci Adv</source><year>2021</year><volume>7</volume><issue>9</issue><fpage>eabe3348</fpage><pub-id pub-id-type="doi">10.1126/sciadv.abe3348</pub-id><pub-id pub-id-type="pmid">33637530</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Cachot A, Bilous M, Liu YC et al (2021) Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Sci Adv 7(9):eabe3348. 10.1126/sciadv.abe3348<pub-id pub-id-type="pmid">33637530</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Crabill</surname><given-names>GA</given-names></name><name><surname>Pritchard</surname><given-names>TS</given-names></name><name><surname>McMiller</surname><given-names>TL</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Pan</surname><given-names>F</given-names></name><name><surname>Topalian</surname><given-names>SL</given-names></name></person-group><article-title>Mechanisms regulating PD-L1 expression on tumor and immune cells</article-title><source>J Immunother Cancer</source><year>2019</year><volume>7</volume><issue>1</issue><fpage>305</fpage><pub-id pub-id-type="doi">10.1186/s40425-019-0770-2</pub-id><pub-id pub-id-type="pmid">31730010</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Chen S, Crabill GA, Pritchard TS, McMiller TL, Wei P, Pardoll DM, Pan F, Topalian SL (2019) Mechanisms regulating PD-L1 expression on tumor and immune cells. J Immunother Cancer 7(1):305. 10.1186/s40425-019-0770-2PMID: 31730010; PMCID: PMC6858680<pub-id pub-id-type="pmid">31730010</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Shurin</surname><given-names>MR</given-names></name><name><surname>Umansky</surname><given-names>V</given-names></name></person-group><article-title>Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy</article-title><source>Shurin MR J Clin Invest</source><year>2022</year><volume>132</volume><issue>9</issue><fpage>e159473</fpage><pub-id pub-id-type="doi">10.1172/JCI159473</pub-id><pub-id pub-id-type="pmid">35499071</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Shurin MR, Umansky V (2022) Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy. Shurin MR J Clin Invest 132(9):e159473. 10.1172/JCI159473PMID: 35499071; PMCID: PMC9057611<pub-id pub-id-type="pmid">35499071</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Noman</surname><given-names>MZ</given-names></name><etal/></person-group><article-title>PD-L1 is a novel direct target of HIF-1&#x003b1;, and its Blockade under hypoxia enhanced MDSC-mediated T cell activation</article-title><source>J Exp Med</source><year>2014</year><volume>211</volume><issue>5</issue><fpage>781</fpage><lpage>790</lpage><pub-id pub-id-type="doi">10.1084/jem.20131916</pub-id><pub-id pub-id-type="pmid">24778419</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Noman MZ et al (2014) PD-L1 is a novel direct target of HIF-1&#x003b1;, and its Blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211(5):781&#x02013;790<pub-id pub-id-type="pmid">24778419</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Ayers</surname><given-names>M</given-names></name><name><surname>Lunceford</surname><given-names>J</given-names></name><name><surname>Nebozhyn</surname><given-names>M</given-names></name><etal/></person-group><article-title>IFN-&#x003b3;-related mRNA profile predicts clinical response to PD-1 Blockade</article-title><source>J Clin Invest</source><year>2017</year><volume>127</volume><issue>8</issue><fpage>2930</fpage><lpage>2940</lpage><pub-id pub-id-type="doi">10.1172/JCI91190</pub-id><pub-id pub-id-type="pmid">28650338</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Ayers M, Lunceford J, Nebozhyn M et al (2017) IFN-&#x003b3;-related mRNA profile predicts clinical response to PD-1 Blockade. J Clin Invest 127(8):2930&#x02013;2940. 10.1172/JCI91190<pub-id pub-id-type="pmid">28650338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>JM</given-names></name><name><surname>Menezes</surname><given-names>AN</given-names></name><name><surname>Ibrahim</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development and validation of a combined hypoxia and immune prognostic classifier for head and neck cancer</article-title><source>Clin Cancer Res</source><year>2019</year><volume>25</volume><issue>17</issue><fpage>5315</fpage><lpage>5328</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-3314</pub-id><pub-id pub-id-type="pmid">31182433</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Brooks JM, Menezes AN, Ibrahim M et al (2019) Development and validation of a combined hypoxia and immune prognostic classifier for head and neck cancer. Clin Cancer Res 25(17):5315&#x02013;5328. 10.1158/1078-0432.CCR-18-3314Epub 2019 Jun 10. PMID: 31182433<pub-id pub-id-type="pmid">31182433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Dave</surname><given-names>K</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Magalhaes</surname><given-names>M</given-names></name></person-group><article-title>Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>9705</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-66257-6</pub-id><pub-id pub-id-type="pmid">32546692</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Dave K, Ali A, Magalhaes M (2020) Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study. Sci Rep 10(1):9705. 10.1038/s41598-020-66257-6PMID: 32546692; PMCID: PMC7297711<pub-id pub-id-type="pmid">32546692</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>F</given-names></name><name><surname>Franzen</surname><given-names>A</given-names></name><name><surname>de Vos</surname><given-names>L</given-names></name><etal/></person-group><article-title>CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma</article-title><source>Clin Epigenetics</source><year>2023</year><volume>15</volume><issue>1</issue><fpage>112</fpage><pub-id pub-id-type="doi">10.1186/s13148-023-01525-6</pub-id><pub-id pub-id-type="pmid">37415208</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Hoffmann F, Franzen A, de Vos L et al (2023) CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma. Clin Epigenetics 15(1):112. 10.1186/s13148-023-01525-6PMID: 37415208; PMCID: PMC10327338<pub-id pub-id-type="pmid">37415208</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>NY</given-names></name><name><surname>Ferris</surname><given-names>RL</given-names></name><name><surname>Psyrri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial</article-title><source>Lancet Oncol</source><year>2021</year><volume>22</volume><issue>4</issue><fpage>450</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(20)30737-3</pub-id><pub-id pub-id-type="pmid">33794205</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Lee NY, Ferris RL, Psyrri A et al (2021) Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncol 22(4):450&#x02013;462. 10.1016/S1470-2045(20)30737-3<pub-id pub-id-type="pmid">33794205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Julian</surname><given-names>R</given-names></name><name><surname>Savani</surname><given-names>M</given-names></name><name><surname>Bauman</surname><given-names>JE</given-names></name></person-group><article-title>Immunotherapy approaches in HPV-Associated head and neck Cancer</article-title><source>Cancers (Basel)</source><year>2021</year><volume>13</volume><issue>23</issue><fpage>5889</fpage><pub-id pub-id-type="doi">10.3390/cancers13235889</pub-id><pub-id pub-id-type="pmid">34884999</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Julian R, Savani M, Bauman JE (2021) Immunotherapy approaches in HPV-Associated head and neck Cancer. Cancers (Basel) 13(23):5889. 10.3390/cancers13235889<pub-id pub-id-type="pmid">34884999</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Bla&#x0017e;ek</surname><given-names>T</given-names></name><name><surname>Petr&#x000e1;&#x00161;</surname><given-names>M</given-names></name><name><surname>Knybel</surname><given-names>L</given-names></name><name><surname>Cvek</surname><given-names>J</given-names></name><name><surname>Soumarov&#x000e1;</surname><given-names>R</given-names></name></person-group><article-title>Programmed cell death ligand 1 expression on immune cells and survival in patients with nonmetastatic head and neck cancer: a systematic review and meta-analysis</article-title><source>JAMA Netw Open</source><year>2023</year><volume>6</volume><issue>3</issue><fpage>e236324</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.6324</pub-id><pub-id pub-id-type="pmid">37000447</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Bla&#x0017e;ek T, Petr&#x000e1;&#x00161; M, Knybel L, Cvek J, Soumarov&#x000e1; R (2023) Programmed cell death ligand 1 expression on immune cells and survival in patients with nonmetastatic head and neck cancer: a systematic review and meta-analysis. JAMA Netw Open 6(3):e236324. 10.1001/jamanetworkopen.2023.6324<pub-id pub-id-type="pmid">37000447</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Immunotherapy advances in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma and its relationship with human papillomavirus</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><fpage>652054</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2021.652054</pub-id><pub-id pub-id-type="pmid">34305889</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Wang H, Zhao Q, Zhang Y et al (2021) Immunotherapy advances in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma and its relationship with human papillomavirus. Front Immunol 12:652054. 10.3389/fimmu.2021.652054<pub-id pub-id-type="pmid">34305889</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>